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Abstract
Background: Studies have associated obesity with better outcomes in comparison to non-obese patients after
elective and emergency coronary revascularization. However, these findings might have been influenced by patient
selection. Therefore we thought to look into the obesity paradox in a consecutive network STEMI population.
Methods: The database of two German myocardial infarction network registries were combined and data from a
total of 890 consecutive patients admitted and treated for acute STEMI including cardiogenic shock and
cardiopulmonary resuscitation according to standardized protocols were analyzed. Patients were categorized in
normal weight (≤24.9 kg/m2), overweight (25-30 kg/m2) and obese (>30 kg/m2) according to BMI.
Results: Baseline clinical parameters revealed a higher comorbidity index for overweight and obese patients; 1-year
follow-up comparison between varying groups revealed similar rates of all-cause death (9.1 % vs. 8.3 % vs. 6.2 %;
p = 0.50), major adverse cardiac and cerebrovascular [MACCE (15.1 % vs. 13.4 % vs. 10.2 %; p = 0.53)] and target
vessel revascularization in survivors [TVR (7.0 % vs. 5.0 % vs. 4.0 %; p = 0.47)] with normal weight when compared to
overweight or obese patients. These results persisted after risk-adjustment for heterogeneous baseline characteristics of
groups. An analysis of patients suffering from cardiogenic shock showed no impact of BMI on clinical endpoints.
Conclusion: Our data from two network systems in Germany revealed no evidence of an “obesity paradox”in an
all-comer STEMI population including patients with cardiogenic shock.
Keywords: Coronary stent, Obesity paradox, Mortality, Cardiogenic shock
Background
Obesity and associated disorders like hypertension, hyper-
lipidemia and diabetes are linked to increased morbidity
and mortality among a Western population [1, 2]. This pa-
tient cohort is also at greater risk to develop coronary ar-
tery disease [2]. Population-based registry data revealed
that 43 % and 24 % of coronary revascularizations were
carried out in overweight and obese patients, respectively
[3]. However, despite evidence of a positive correlation
between obesity and increased cardiovascular morbidity,
previous studies have described an “obesity paradox” in
patients undergoing coronary revascularization either by
interventional (PCI) or surgical (CABG) strategies, report-
ing a protective effect of obesity in terms of postoperative
mortality. The first description of this phenomenon was
done by Gruberg et al. 12 years ago [4]. Although the im-
pact of obesity on clinical outcomes after elective PCI has
been subsequently investigated in several studies, the issue
remains controversial. Thus, there is insufficient data in
unselected populations suffering from acute coronary syn-
drome (ACS), which is additionally associated with a com-
plex thrombogenic and proinflammatory status [5–10].
Our current analysis compares clinical outcomes after PCI
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between consecutive normal weight, overweight and obese
patients diagnosed with an ST-segment elevation myocar-




Both myocardial infarction networks, which were the first
networks in Germany, aim at coronary reperfusion ther-
apy with primary PCI as the treatment prerogative for all
presumed STEMI patients according to a uniform, re-
gional treatment protocol patterned for a 24 h/7days week
in a single interventional centre.
“Network A”, located in northeastern Germany con-
stituted a mixed urban and rural catchment area with
an approximate population of 415,000 inhabitants and
was spread across a 60 km radius from its centre. At
the time of collecting data, there were eight hospitals
in the network area, with a lone high-volume inter-
ventional facility functioning as a 24 h/7days primary
PCI service point. Emergency Medical Services (EMS)
transferred suspected STEMI patients to the emer-
gency department of the nearest hospital without
prior announcement. Upon arrival of the patient, local
emergency departments alarmed the interventional
cardiology team and organized the direct transfer of
the patient to the cathlab.
“Network B”, located in southwestern Germany, consti-
tuted a rural catchment area with approximately 350,000
inhabitants and was spread across a 35 km radius from its
centre. At the time of data collection there were six hospi-
tals in this network area, with a lone high-volume inter-
ventional facility functioning as a 24 h/7days primary PCI
service point.
Trained personnel at all collection points supported
both Network structures. All STEMI patients, irrespective
of cardiogenic shock or preceding cardiopulmonary resus-
citation were intended for primary PCI through femoral
access.
Primary PCI protocol
All provisionally diagnosed STEMI patients were treated
with 250–500 mg Aspirin intravenously and received a
weight adjusted unfractionated dose of Heparin (70 IU/
kg) by EMS. The loading dose of clopidogrel (600 mg)
was mostly administered before the PCI. In few cases,
this was administered immediately after the procedure.
When treating patients in shock, interventional
cardiologists were encouraged to treat all presumed
hemodynamically relevant non-target lesions. Thrombec-
tomy, periprocedural GPIIb/IIIa blockers (predominantly
abciximab) and drug-eluting stents (DES) were utilized at
the discretion of the operator. The full anticoagulant dos-
ing of heparin was stopped after PCI, unless there was a
high risk of thromboembolism (eg. atrial fibrillation or
mechanical heart valves).
Study population
Consecutive STEMI patients admitted for primary
PCI were prospectively included in their respective
registries, in network A from 2001 to 2003 and in
network B from 2005 to 2007.
Definitions
These were based on parameters defined by the
World Health Organization (WHO) and the National
Heart, Lung and Blood Institute. The patient popula-
tion was classified into normal weight (body mass
index [BMI] 18.5 - 24.9 kg/m2), overweight (BMI 25–
30 kg/m2) and obese group (>30 kg/m2) [11, 12].
STEMI was diagnosed by the presence of chest pain
lasting > 20 min and of significant ST-segment eleva-
tion (≥0.1 mV in two adjacent leads if leads I-III, aVF,
aVL, V4-V6, and ≥ 0.2 mV in leads V1-V3), as in the
first recorded electrocardiogram (ECG). Patients with
persistent angina and presumably new left bundle
branch block (LBBB) were included in the registry if
myocardial infarction (MI) was subsequently con-
firmed. Cardiogenic shock was defined clinically by
the presence of hypotension (systolic blood pressure <
90 mmHg for >30 min or need for vasopressors to
maintain systolic blood pressure >90 mmHg) and
tachycardia (heart rate >90 beats/min) with evidence
of end-organ hypoperfusion [13]. Thrombolysis In
Myocardial Infarction (TIMI) flow grades were
assessed in the culprit vessel before and after the PCI
procedure. Major bleeding was defined according to
the TIMI major bleeding definition as intracerebral
bleeding, bleeding requiring surgical intervention,
bleeding requiring transfusion or loss of more than
5 g/% haemoglobin [14]. As indicators of guideline
adherent therapy we analyzed pre- and in-hospital de-
lays, procedural success of primary PCI, stent use,
peri-interventional antiplatelet management, medica-
tion at discharge and medication at 12 months [15].
Procedural success was defined as residual stenosis <
30 % of the culprit lesion. For outcomes we analyzed
mortality, re-infarction rate, target lesion revasculari-
zation (TLR) and target vessel revascularization
(TVR) up to 12 months. TVR included repeat proce-
dures, either PCI or CABG, in the target vessel. The
composite of these events was defined as the major
adverse cardiac and cerebrovascular events (MACCE)
including death, MI, TVR and stroke. Patients were
discouraged to undergo routine angiography for
follow-up; therefore, all re-interventions can be
counted as clinically driven. Stent thrombosis (ST)
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was classified according to the definition proposed by
the Academic Research Consortium (ARC) [16].
Data collection and follow-up
All patients diagnosed with STEMI were cataloged in a
dedicated database. The procedure for follow-up usually
included telephone interviews and subject-based question-
naires at the time frame of 6 and 12 months. A descriptive
follow-up concerning mortality was obtained from state
registries. The local ethics committees in Rostock (Med-
ical Faculty of University Rostock, Germany) and Freiburg
(Albert-Ludwigs-University Freiburg, Germany) approved
the registries. All patients included in this study gave pre-
emptive informed consent for the extension of our routine
follow-up.
Statistical methods
Data was analyzed according to established standards
of descriptive statistics. Categorical variables were
compared by chi2 test. Continuous variables were re-
ported as mean ± standard deviation or median with
interquartile ranges. For comparisons, the t test, the
two-tailed Mann–Whitney U test and ANOVA model
was used where appropriate. Odds ratios (OR) and
95 % confidence intervals (CI) were provided where
appropriate. A p value of less than 0.05 was consid-
ered significant. A multivariate logistic regression ana-
lysis (stepwise backward model) including sex, age,
diabetes, hypertension, smoking, renal failure, cardio-
genic shock, resuscitation, stent type and impaired
ejection fraction (<45 %) at discharge with normal
weight as a fixed parameter was performed to deter-
mine independent factors predicting 12-month mor-
tality and MACCE. The final logistic model for 12-
month mortality with the independent variables age,
diabetes and impaired ejection fraction (<45 %) at dis-
charge showed a good predictive value (C-statistic =
0.84), and good calibration characteristics using the
Hosmer-Lemeshow test (p = 0.90). Mortality and
MACE at 12 months was adjusted for the above-
mentioned variables. One-year survival was demon-
strated by Kaplan-Meier curves and compared by log-
rank test.
Results
Baseline characteristics and procedural outcomes
Our analysis is based on the 890 patients diagnosed with
STEMI between 2001 and 2007 in this prospective study
at the two participating centers. Patients were categorized
as normal weight (n = 263), overweight (n = 432) and
obese (n = 195) with a mean BMI of 23.2 ± 1.72 kg/m2
27.2 ± 1.32 kg/m2, and 32.9 ± 2.83 kg/m2, respectively.
Obese patients were younger than overweight and normal
weight patients (65.7 ± 12.87 vs. 62.8 ± 11.70 vs. 60.4 ±
11.67; p < 0.0001) and had a higher comorbidity index
with higher rates of diabetes (13.3 % vs. 19.5 % vs. 27.2 %;
p < 0.006), and arterial hypertension (48.7 % vs. 63.9 % vs.
73.9 %; p < 0.0001), but with lower rates of impaired renal
function (29.3 % vs. 18.7 % vs. 11.5 %; p < 0.0001)
(Table 1).
Data pertaining to pre-hospital and intra-hospital
time intervals were also not different between groups.
However we observed that normal weight and over-
weight patients suffered more often from cardiogenic
shock (9.9 % vs. 11.1 % vs. 5.1 %; p = 0.02) and had
a higher calculated Grace Score (100.6 ± 16.18 vs.
87.2 ± 12.56 vs. 74.2 ± 10.14; p = 0.02) (Table 2).
Approximately half of all patients included in this study
had a multivessel coronary artery disease with no signifi-
cant difference in the distribution of dual-vessel, triple-
vessel and left-main vessel disease as well as treated target
vessel (Table 2). Primary PCI, being performed through
femoral access in all patients, with implantation of nearly
1.4 ± 0.9 stents per patient was carried out as a single




Patients (n) 263 432 195 <0.0001
Mean BMI, kg/m2 (SD) 23.2 (1.7) 27.2 (1.3) 32.9 (2.8) 0.11
Male (%) 73.0 79.9 75.9








NIDDM 13.3 19.3 26.7
IDDM 0 0.2 0.5
Hypercholesterinemia (%) 45.2 45.8 49.7 <0.0001
Renal insufficiency (%) 29.3 18.7 11.5 <0.0001
Hypertension (%) 48.7 63.9 73.9 <0.0001
Smoking (%)
Current 42.9 37.5 46.7 0.48
Previous myocardial infarction
(%)
11.0 9.5 7.7 0.72
Previous PCI (%) 9.1 7.4 7.7 0.90
Previous CABG (%) 1.5 1.9 2.1 0.92
Previous stroke (%) 4.6 3.9 4.1
Ejection fraction 0.88
>55 % (%) 32.5 30.7 36.1
45-55 % (%) 33.5 37.9 36.2
30-44 % (%) 28.4 25.8 22.0
<30 % (%) 5.6 5.6 5.7
Legend
BMI Body mass index, CAD Coronary artery disease, PCI Percutaneous coronary
intervention, NIDDM Non-insulin dependent diabetes mellitus, IDDM
Insulin-dependent diabetes mellitus, CABG Coronary artery bypass grafting
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vessel PCI in more than 90 % of cases without any change
in strategy between groups. Use of DES was predominant
in the study population. Normal weight patients presented
more often with smaller vessel diameter (Table 3). Al-
though anatomical and procedural characteristics includ-
ing periprocedural complications were comparable the
use of GP IIb/IIIa was more frequent in obese patients
(81.3 % versus 85.7 % versus 94.3 %; p = 0.01).
In-hospital follow-up
The overall in hospital mortality rate was 5.3 % in the nor-
mal weight, 4.4 % in the overweight, and 3.1 % in obese
groups (p = 0.51). Similarly, rates of MI, stroke and bleed-
ing complications as well as need for repeat urgent
revascularization and resuscitation was low with no differ-
ences between subsets (Table 4).
One-year follow-up
At one-year follow-up no significant differences were
noted between groups with respect to the incidence of
MACCE-free survival and TVR-free survival. Similarly,
no differences were noted in the rates of overall death,
MI, stroke, and definite ST (Table 4, Fig. 1). The use of
antiplatelet and anticoagulation treatment was not dif-
ferent between groups.
Subsequent risk-adjustment and multivariate analysis
revealed no impact of overweight and obesity on clinical
events. Predictors for one-year mortality were the pres-
ence of diabetes (OR 2.79; 95 % CI 1.50-5.19), age (OR
1.10; 95 % CI 1.06-1.14) and impaired left ventricular
ejection fraction defined as < 45 % (OR 3.82; 95 % CI
2.05-7.13) without any impact of increasing BMI (OR
1.03; 95 % CI 0.62-1.42). Similarly, predictors for
MACCE at follow-up were increasing age (OR 1.03;
95 % CI 1.01-1.06), while the use of a DES had protect-
ive effects (OR 0.44; 95 % CI 0.24-0.82) without impact
of BMI (OR 0.91; 95 % CI 0.63-1.31).
An exclusion of lean patients (BMI < 18.5 kg/m2; n = 5)
from the normal weight group did not change above-
mentioned intrahospital and follow-up results with similar
event rates in all three groups.
Additionally, a separate analysis of patients suffering
from cardiogenic shock (26 versus 48 versus 8) did not
show any differences between groups with a mean intra-
hospital and one-year follow-up mortality rate of up to
26 % and 31 %, respectively.
Discussion
In Europe, the prevalence of obesity ranges from 4.0 to
36.5 % [17] and it is also well known that obesity acts as
an independent cardiovascular risk factor for the devel-
opment of coronary artery disease as well as general ath-
erosclerosis and is associated with increased overall
morbidity and mortality [18, 19]. There is evidence
that this increased risk is mediated through obesity-
related co-morbidities such as diabetes mellitus,
hyperlipidemia, hypertension, increased insulin resist-
ance, enhanced free fatty acid turnover, and promo-
tion of systemic inflammation [20]. However, despite
this correlation there is an assumption of an inverse
correlation of obesity with mortality post PCI and less
pronounced with a smaller need for repeat revascular-
isation. This has been described as the “obesity para-
dox” [10, 21]. An analysis of 9,633 patients being
stratified in normal weight (n = 1,923), overweight (n
= 4,813) and obese (n = 2,897) undergoing PCI re-
vealed a higher incidence of major in-hospital compli-
cations, including cardiac death (1.0 % vs. 0.7 % vs.
Table 2 Descriptive morphology of coronary artery disease in




Single 47.1 48.0 50.5 0.78
Dual 28.8 28.4 29.4
Triple 22.6 21.5 19.6
Left main stenosis (%) 2.5 3.0 1.0
Target vessel (%)
LAD 48.1 44.0 47.2 0.55
LCX 16.5 16.7 11.4
RCA 34.6 37.4 40.4
LMCA 0.8 1.9 0.5
Bypass graft 0 0 0.5
TIMI-flow (%)
0 62.0 55.8 65.6 0.65
1 8.2 8.4 8.3
2 12.7 16.8 13.5
3 17.1 19.0 12.6
Grace score (%) 100.6 (87.6) 87.2 (77.6) 74.2 (53.8) 0.02
CPR (%) 9.1 8.1 5.1 0.25
Cardiogenic shock (%) 9.9 11.1 5.1 0.02
Fibrinolysis prior
PCI (%)
1.1 1.2 2.6 0.35
Pain-to-door time,
min (SD)
212.2 (164.0) 212.5 (154.6) 213.6 (165.2) 0.99
Door-to-lab time,
min (SD)
30.2 (67.9) 27.9 (46.5) 26.0 (46.3) 0.73
Lab-to-balloon time,
min (SD)
30.8 (15.21) 31.4 (16.5) 32.6 (15.6) 0.67
Legend
LAD Left anterior descending coronary artery, LCX Left circumflex coronary
artery, RCA Right coronary artery, LMCA Left main coronary artery, TIMI
Thrombolysis in myocardial infarction, CPR cardiopulmonary resuscitation
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0.4 %; p = 0.001) in normal weight than overweight
and obese patients despite similar periprocedural data.
This was driven by overall mortality (10.6 % vs. 5.7 %
vs. 4.9 %; p < 0.0001). Cardiac mortality (4.8 % versus
3.3 % versus 2.5 %; p < 0.0001) was also significantly
higher in normal weight patients; whereas rates of MI
and TVR were similar [10]. A large meta-analysis in-
cluding 250,152 patients with established coronary ar-
tery disease and a mean follow-up of 3.8 years
supported these findings with increased relative risk
for overall mortality [RR 1.37 (95 % CI 1.32-1.43)],
and cardiovascular mortality [RR 1.45 (1.16-1.81)]
after revascularization in normal weight patients [22].
These results persisted even after adjustment for po-
tential confounders, including age, arterial hyperten-
sion, diabetes, and left ventricular function. Another
analysis on patients with established coronary artery
disease undergoing medical, interventional or surgical
treatment showed an “obesity paradox” after revascu-
larisation irrespective of the chosen strategy. In the
whole cohort patients who were overweight or obese
were more likely to undergo revascularization proce-
dures compared with those with normal BMI, despite
having lower risk coronary anatomy [23]. The under-
lying mechanism of the “obesity paradox” is specula-
tive. Obesity is associated with lower levels of plasma
renin, epinephrine and high serum levels of low-
density lipoproteins that bind circulating lipopolysac-
charides [24]. Coronary vessel diameters, as confirmed
in out-patient cohorts, have been shown to correlate
with the increase in body weight; thus a smaller cor-
onary artery size in normal weight and lean patients
could theoretically influence periprocedural outcome
[25]. The relationship between obesity and survival is
characterized in the literature by a J- or U-shaped
curve with increasing mortality in the very lean or se-
verely obese group [26, 27]; however, after adjustment
for smoking and concurrent illness, the relationship
has always been linear [28, 29]. Contrasting with
these findings our analysis of high-risk all-comers
STEMI population including patients with cardiogenic
shock does not support the presence of an “obesity
paradox”. Although there is a trend for better one-
year survival in obese patients, this difference did not
reach statistical significance. However, with access site
being femoral there might be more bleeding events in
obese patients, which could be avoided by radial ac-
cess. Nevertheless, we think that the term “obesity
paradox” might predominantly reflect different de-
grees of bias that cannot be completely corrected for
by statistical means. Inherent bias in all obesity ana-
lyses result from the fact that overweight and obese




Single vessel PCI (%) 90.8 89.7 96.9 0.30
Multivessel PCI (%) 4.6 5.9 1.0
Staged PCI (%) 23.2 21.8 24.7
Stent details
Number of implanted stents (SD) 1.4 (0.9) 1.4 (0.9) 1.5 (1.0) 0.82
Drug-eluting stents (%) 63.8 61.3 62.9 0.61
Diameter (mm) 3.0 (2.75-3.00) 3.0 (2.80-3.00) 3.0 (2.80-3.50) 0.030
Length (mm) 24.0 (20.0-35.0) 24.0 (20.0-38.0) 24.0 (22.0-36.0) 0.47
Postprocedural TIMI III (%) 84.1 82.3 82.3 0.29
Periprocedural complication (%)
No-reflow 0 2.0 3.0 0.12
Complete AV-block 3.0 2.0 0 0.18
CPR 1.0 3.0 2.0 0.66
Stroke / TIA 1.0 0 0 0.74
Death 0 0 1.0 0.46
No complication during incex PCI 94.0 95.0 94.0 0.94
GP IIb/IIIA antagonist (%) 81.3 85.7 94.3 0.01
Legends
TIMI Thrombolysis in myocardial infarction, GP Glycoprotein, PCI percutaneous coronary intervention, AV atrioventricular node, CPR cardiopulmonary resuscitation,
TIA transient cerebral ischemic attack
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patients are usually younger and have larger culprit
coronary vessel diameters than normal weight coun-
terparts. In general younger patients have better clin-
ical outcomes after acute MI regardless of reperfusion
modality [30, 31]. Additionally, the presence of co-
morbidities in obese and overweight younger patients
usually leads to more aggressive therapy of cardiovas-
cular risk factors likely to improve outcomes despite
obesity [30, 31]. In a study of 130,139 patients hospi-
talized for coronary artery disease, higher BMI was
associated with increased use of standard medical
therapies such as aspirin, beta-blockers, renin-
angiotensin inhibitors, and lipid lowering therapy, and
an increased likelihood of undergoing diagnostic
catheterization and revascularization [32, 33]. The all-
comer design of our registry with the majority of pa-
tients having had no established coronary artery dis-
ease before the index STEMI reduces the influence of
potential confounders. Especially promotion of pri-
mary PCI in shock patients and after resuscitation
(significantly more frequent in obese and overweight
patients) avoided a severe pre-selection bias. Another
point of discussion with respect to the obesity paradox
is that underweight patients may receive standard anti-
coagulation doses that are too high for their body size,
making them more prone to post-procedural bleeding
complications, which could be ruled out in our cohort
by weight-adjusted doses [3, 5]. In addition obesity was
found to correlate with higher levels of factor VII, VIII,
fibrinogen and plasminogen activator inhibitor-1,
which were all associated with increased risk of throm-
bosis [34]. Accordingly prospective investigations have
shown that overweight and obese patients were more
likely to suffer from suboptimal platelet response to
clopidogrel and aspirin treatment [35, 36]. In our co-
hort the use of GP IIb/IIIa inhibitor was high facing
the nature of exclusively high-risk STEMI patients.
Furthermore obesity as well as STEMI is considered a
low-grade inflammatory state, as demonstrated by in-
creased levels of the pro-inflammatory cytokines
interleukin-6 and tumor necrosis factor-alpha, and
acute phase proteins such as C-reactive protein [37].
This proinflammatory state may also directly and in-
directly cause thrombosis by oxidative stress and endo-
thelial dysfunction [38]. Such findings could not be
confirmed in our real-world setting with similar rates
of stent thrombosis in all subsets. Since low BMI may
be a marker of severe systemic illness [18, 39], we de-
fined in a separate analysis the normal-weight group
from 18.5 kg/m2-24.9 kg/m2 and excluded 5 extremely
underweight patients. However, this did not change
the previous findings with lack of an “obesity paradox”.
A separate analysis of patients with cardiogenic shock,
which is associated with a prothrombic situation and
Fig. 1 One-year overall survival of population stratified in normal
weight, overweight and obese groups





Death (%) 5.3 4.4 3.1 0.51
Myocardial infarction (%) 0.6 0 2.0 0.09
Stroke (%) 1.0 0 0 0.45
Repeat urgent revascularization (%)
PCI 1.0 0 2.0 0.31
CABG 1.0 0 0 0.35
CPR (%) 2.0 2.0 0 0.41
Complete AV-block (%) 1.0 0 1.0 0.25
Aneurysma spurium (%) 1.0 2.0 0 0.43
Bleeding (%)
Major 1.9 3.4 1.0 0.37
Minor 6.9 7.3 3.1 0.33
Insignificant 17.6 14.2 13.3 0.56
Triple antiplatelet therapy (%) 14.5 9.4 10.6 0.27
One-year follow-up
Death (%) 9.1 8.3 6.2 0.50
Myocardial infarction (%) 5.7 4.7 5.1 0.92
Stroke (%) 0 1.3 1.0 0.37
MACCE (%) 15.1 13.4 10.2 0.53
TVR (%) 7.0 5.0 4.0 0.47
Definite ST according ARC (%) 4.0 2.0 1.0 0.26
ASS 70.6 69.0 74.4 0.66
Clopidogrel 46.9 37.6 48.9 0.13
Oral anticoagulation (%) 4.2 8.5 5.6 0.24
Legends
PCI Percutaneous coronary intervention, CABG Coronary bypass graft, CPR
Cardiopulmonary resuscitation, MACCE Major adverse cardiac and
cerebrovascular event, TVR Target vessel revascularization, ST Stent
thrombosis, ARC Academic Research Consortium
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systemic inflammation, also revealed no statistical dif-
ferences in clinical endpoints for all three groups.
Study limitation
The present study is an observational non-randomized
study in which patients were stratified according to their
BMI at index-PCI. Thus, we had no information on
intended or unintended weight change, as well as on
variables like physical inactivity and socioeconomic fac-
tors which may have influenced the results. BMI is not
as well correlated to cardiovascular disease and death as
waist circumference and waist-to-hip ratio, which, how-
ever, were unavailable in our registries. Another limita-
tion of our analysis is the length of follow-up and small
sample size that might result in lack of power for mean-
ingful conclusions but is reliable enough for hypothesis
generation. An extended follow-up may result in a cu-
mulative detrimental effect of obesity and may even
manifest as increased late mortality and confirm the
negative correlation of obesity with clinical outcomes
even in a setting of coronary revascularization. Addition-
ally the access site during PCI was femoral. With use of
radial access site, bleeding events might be reduced in
overweight and obese patients, which might result in
better clinical outcomes as bleeding events correlate
with overall mortality and myocardial infarction rate.
Conclusions
Data from our all-comer network registry does not con-
firm the evidence of the “obesity paradox” during short
and long term follow-up in patients suffering from STEMI
including patients with cardiogenic shock. With respect to
the limitations of available data prospective large-scale
studies with long-term follow-up focusing on more reli-
able parameters reflecting the body fat are needed to re-
veal the phenomenon of the obesity paradox.
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